Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.It is the largest pharmaceutical company in India.
What Sun files
- Others66
- Updates46
- Investor Meet43
- Important26
- Dividend/Bonus8
- PPTs7
Sun Pharma shareholders passed key resolutions, including changes to the company's main business objectives and re-appointing Dr. Pawan Goenka as an Independent Director. These moves could shape future strategic direction.
Sun Pharma launched a Shareholder Satisfaction Survey to gather feedback on its RTA services. This aims to boost service quality and efficiency for investors who used RTA services between April and December 2025. Share your valuable input!
Sun Pharma reported robust FY25 performance with ₹85,462.9 Cr revenue & ₹10,929 Cr profit. ESG strides include 21% Scope 1&2 emissions cut, 25% water reduction (exceeding targets), and 41% renewable energy. R&D investments hit ₹3,250 Cr. Operational integrity remained high, with only minor recalls and no significant compliance issues.
Sun Pharma's subsidiary approved a ₹3,000 Cr investment for a new greenfield formulations manufacturing facility in Madhya Pradesh, signaling future capacity expansion and growth.
Sun Pharma, with $6.2 billion revenue, released its ESG Overview. Key highlights: ~21% carbon, 25% water reduction (vs 2020 baseline), 41% renewable energy. R&D spend 6.2%. Zero Class-I recalls, 4 USFDA observations. Sales programs drove 15.1% revenue growth; manager program boosted production efficiency by 9%.